RAWGA, $315M Strategic Partnership with Li Shizhen Pharmaceutical Group

RAWGA, $315M Strategic Partnership with Li Shizhen Pharmaceutical Group
We are proud to announce a landmark 5-year, $315 Million (KRW 420B) deal to bring RAWGA’s plant-based bio-technology to the heart of the Chinese market.

This isn't just an MOU—it's a massive leap forward in the global validation of Plant-Based Science.

Key Highlights:

🤝 Strategic Partner: Li Shizhen Pharmaceutical Group (Top 100 Chinese Pharma)
💰 Immediate Impact: $4M initial purchase order confirmed at signing
🧪 Tech Edge: Global expansion of VC-H1Ⓡ, the world’s first plant-based hydrolyzed collagen
🔬 Beyond Supply: Deep R&D collaboration to set new standards in premium medical and inner-beauty materials

This partnership proves that our plant-based technology is now a recognized global standard.
From China to the world, we are redefining the future of wellness.


#RAWGA #PlantBased #BioTech #GlobalBusiness #InnerBeauty #FutureOfWellness #LiShizhenGroup